FUNDAMENTALS · Fundamentals · KR Technology

UTI (179900) Fundamentals 2026 — Revenue Analysis | SniperIQ

UTI (179900) is a KR-listed Technology company in Hardware, Equipment & Parts with a market capitalization of ₩54.2B, trading at ₩2770.00 on the KOE. This SniperIQ fundamentals page covers UTI's valuation, profitability (net margin -207.7%), revenue (₩20.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩54.2B
Net Margin-207.7%
Revenue (FY25)₩20.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is UTI's market cap?

UTI (179900) has a market capitalization of approximately ₩54.2B, trading at ₩2770.00 on the KOE. Market cap moves with the live share price.

What is UTI's P/E ratio?

UTI's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Technology sector peers rather than read in isolation.

How profitable is UTI?

UTI runs a net profit margin of -207.7%, a gross margin of -113.1%, and an operating margin of -224.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does UTI generate?

UTI reported revenue of ₩20.0B for fiscal year 2025, with net income of -₩37.4B and earnings per share (EPS) of -2041.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does UTI pay a dividend?

UTI does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is UTI financially healthy?

UTI carries a debt-to-equity ratio of 1.57x and a current ratio of 0.44x, with a market beta of 1.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is UTI a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For UTI (179900) the key facts are: market cap ₩54.2B, revenue ₩20.0B, 52-week range 2715-29300. Weigh valuation, profitability, growth, and balance-sheet strength against Technology peers and form your own view.

Track UTI's full fundamentals live

Get UTI's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Optiemus Infracom (OPTIEMUS) fundamentals · Nebius Group (NBIS) fundamentals · Hangzhou Silan Microelectronics (600460) fundamentals · I-Chiun Precision Industry (2486) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons